Get the Stockscreener App
5.45
0.91%
-0.05
After Hours:
5.17
-0.28
-5.14%
Hcw Biologics Inc stock is traded at $5.45, with a volume of 44,767.
It is down -0.91% in the last 24 hours and down -45.77% over the past month.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
See More
Previous Close:
$5.50
Open:
$5.33
24h Volume:
44,767
Relative Volume:
0.07
Market Cap:
$12.04M
Revenue:
$3.50M
Net Income/Loss:
$-37.33M
P/E Ratio:
-5.45
EPS:
-1
Net Cash Flow:
$-19.15M
1W Performance:
-9.77%
1M Performance:
-45.77%
6M Performance:
-61.83%
1Y Performance:
-87.80%
1-Day Range:
$5.20
$5.60
1-Week Range:
$5.16
$6.15
52-Week Range:
$5.0001
$100.80
Hcw Biologics Inc Stock (HCWB) Company Profile
Name
Hcw Biologics Inc
Sector
Industry
Phone
954-842-2024
Address
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
5.45 | 12.04M | 3.50M | -37.33M | -19.15M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Hcw Biologics Inc Stock (HCWB) Latest News
HCW Biologics (NASDAQ:HCWB) Rating Lowered to “Sell” at Wall Street Zen - Defense World
HCW Biologics Sees Strong Investor Interest in June - TipRanks
HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Down 85.9% in May - Defense World
HCW Biologics (NASDAQ:HCWB) Trading Down 7.6% – Here’s What Happened - Defense World
Wall Street Zen Upgrades HCW Biologics (NASDAQ:HCWB) to “Hold” - Defense World
HCW Biologics Meets Nasdaq Listing Requirements in May 2025 - TipRanks
HCW Biologics partners with WY Biotech for immunotherapy By Investing.com - Investing.com South Africa
HCW Biologics Secures Licensing Agreement with WY Biotech - TipRanks
HCW Biologics partners with WY Biotech for immunotherapy - Investing.com Australia
HCW Biologics (HCWB) Secures $7M Upfront License Fee in New Agreement with WY Biotech | HCWB Stock News - GuruFocus
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech - GlobeNewswire
HCW Biologics Engages Armistice in Securities Purchase - TipRanks
HCW Biologics (NASDAQ:HCWB) Price Target Lowered to $35.00 at Maxim Group - Defense World
HCW Biologics (HCWB) Price Target Adjusted by Maxim | HCWB Stock News - GuruFocus
HCWB: Maxim Group Maintains Buy Rating, Lowers Price Target | HC - GuruFocus
HCWB: Maxim Group Maintains Buy Rating, Lowers Price Target | HCWB Stock News - GuruFocus
HCW Biologics Issues Shares Through Warrant Exercise - TipRanks
Insider Buying: Hing Wong Acquires Additional Shares of HCW Biol - GuruFocus
HCW Biologics Enters Securities Purchase Agreement - TipRanks
HCW Biologics (NASDAQ:HCWB) Trading 9.1% Higher – Still a Buy? - Defense World
HCW Biologics Inc Reports Q1 2025 Earnings: Revenue at $5,065, Net Loss Reduced to $2.2 Million - GuruFocus
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results - The Manila Times
HCW Biologics Inc. Reports Q1 2025 Financial Results and $5 Million Equity Offering Completion - Nasdaq
HCW Biologics Closes $5 Million Public Offering - TipRanks
HCW Biologics (HCWB) Launches $5M Follow-On Offering - GuruFocus
HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - The Manila Times
HCW Biologics Raises Fresh Capital: $5M Follow-On Offering Includes Attractive Warrant Package - Stock Titan
HCWB Announces Maxim Group LLC as Sole Placement Agent for Offer - GuruFocus
HCWB Announces Maxim Group LLC as Sole Placement Agent for Offering | HCWB Stock News - GuruFocus
Three layers of uncertainty - The Globe and Mail
Nasdaq Rises Over 1%; Under Armour Posts Strong Q4 Sales - Benzinga
Trading Halt for HCW Biologics (HCWB) Due to Volatility | HCWB S - GuruFocus
Trading Resumes for HCW Biologics (HCWB) | HCWB Stock News - GuruFocus
HCW Biologics Reports Positive Results For HCW9206 And Opens Commercial Partnership Talks - Nasdaq
HCW Biologics Says Studies Show HCW9206 Fusion Protein Addresses Key Challenges for CAR-T Therapies; Shares Surge - marketscreener.com
HCW Biologics (HCWB) Unveils Innovative Pathway for Enhanced CAR - GuruFocus
HCW Biologics presents novel CAR-T cell enhancer By Investing.com - Investing.com Nigeria
HCW Biologics presents novel CAR-T cell enhancer - Investing.com
HCW Biologics Announces Positive Results of Studies of - GlobeNewswire
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization - TradingView
Friday’s Insider Moves: Top Buys and Sells in US Stocks Revealed By Investing.com - Investing.com South Africa
Friday’s Insider Moves: Top Buys and Sells in US Stocks Revealed - Investing.com
Prediction: Warren Buffett May Be Shifting Out of His Berkshire Hathaway CEO Role, but He's Not Done Investing - The Globe and Mail
Should You Buy Rivian Stock While It Is Still Below $15? - The Globe and Mail
This Well-Known Toy Company Is Set to Be an Outperformer if the Tariff War Continues - The Globe and Mail
Insider Buying: Gary Winer Acquires Shares of HCW Biologics Inc (HCWB) - GuruFocus
Hcw biologics CEO acquires $2.41 million in stock By Investing.com - Investing.com Nigeria
Hcw Biologics Inc Stock (HCWB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):